Oncotarget

Reviews:

Next-generation metabolomics in lung cancer diagnosis, treatment and precision medicine: mini review

Li Yu, Kefeng Li and Xiaoye Zhang _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:115774-115786. https://doi.org/10.18632/oncotarget.22404

Metrics: PDF 701 views  |   HTML 1889 views  |   ?  


Abstract

Li Yu1, Kefeng Li2 and Xiaoye Zhang1

1Department of Oncology, Shengjing Hospital, China Medical University, Shenyang, Liaoning, China

2School of Medicine, University of California San Diego, San Diego, CA, USA

Correspondence to:

Xiaoye Zhang, email: zhangxy1@sj-hospital.org

Keywords: next-generation metabolomics; lung cancer; precision medicine; biomarker; pathogenesis

Received: May 24, 2017    Accepted: September 21, 2017    Published: November 11, 2017

ABSTRACT

Lung cancer is the leading cause of cancer-related death. Next-generation metabolomics is becoming a powerful emerging technology for studying the systems biology and chemistry of health and disease. This mini review summarized the main platforms of next-generation metabolomics and its main applications in lung cancer including early diagnosis, pathogenesis, classifications and precision medicine. The period covers between 2009 and August, 2017. The major issues and future directions of metabolomics in lung cancer research and clinical applications were also discussed.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 22404